» Articles » PMID: 10362144

Influence of MUC18/MCAM/CD146 Expression on Human Melanoma Growth and Metastasis in SCID Mice

Overview
Journal Int J Cancer
Specialty Oncology
Date 1999 Jun 11
PMID 10362144
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The cell surface glycoprotein MUC18MCAM/CD146 was originally defined as a marker of melanoma progression and has been suspected to be directly linked to the metastatic process of this malignancy. In order to address this question, 2 MCAM negative human melanoma cell lines, SK-2 and XP44RO(Mel), were transfected with MCAM-encoding cDNA. Surface MCAM expression on SK-2 and XP44RO(Mel) transfectants was similar to that observed in naturally occurring MCAM positive human melanoma cells and transfectants demonstrated MCAM-dependent increase in homotypic adhesion in vitro. The growth behavior of 7 MCAM transfectants and their respective vector controls was evaluated in SCID mice. Tumor size at 4-5 weeks after s.c. implantation was highly variable, but did not correlate with MCAM expression. Despite massive primary tumor formation at the injection site, no spontaneous metastasis was observed with any of the investigated MCAM transfectants. The influence of MCAM expression on lung metastases formation in an experimental metastasis assay was system dependent, converting only XP44RO(Mel) transfectants into metastatic cells, although increased homotypic adhesion, leading to formation of tumor cell clusters, was observed with transfectants of both cell lines in vitro. Our findings indicate that MCAM expression of human melanoma cells has an influence on later stages of the metastatic process only, namely, extravasation and establishment of new foci of growth, but is per se not sufficient for this process.

Citing Articles

The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.

Mohammed N, Antonopoulos A, Dell A, Haslam S, Dimitroff C Adv Cancer Res. 2023; 157:157-193.

PMID: 36725108 PMC: 9895887. DOI: 10.1016/bs.acr.2022.06.001.


The tendon interfascicular basement membrane provides a vascular niche for CD146+ cell subpopulations.

Marr N, Zamboulis D, Werling D, Felder A, Dudhia J, Pitsillides A Front Cell Dev Biol. 2023; 10:1094124.

PMID: 36699014 PMC: 9869387. DOI: 10.3389/fcell.2022.1094124.


METCAM/MUC18 Plays a Tumor Suppressor Role in the Development of Nasopharyngeal Carcinoma Type I.

Liu Y, Chen Y, Wu G Int J Mol Sci. 2022; 23(21).

PMID: 36362174 PMC: 9655335. DOI: 10.3390/ijms232113389.


Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination.

Sharma A, Joshkon A, Ladjimi A, Traboulsi W, Bachelier R, Robert S Int J Mol Sci. 2022; 23(2).

PMID: 35055160 PMC: 8780963. DOI: 10.3390/ijms23020974.


Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors.

Stalin J, Nollet M, Dignat-George F, Bardin N, Blot-Chabaud M Antibodies (Basel). 2019; 6(4).

PMID: 31548532 PMC: 6698816. DOI: 10.3390/antib6040017.